The University of Chicago Header Logo

Daniel H. Shevrin

InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123. PMID: 38261983.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    2. Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci M. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563. PMID: 37422371; PMCID: PMC10515442.
      Citations: 3     Fields:    Translation:Humans
    3. Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, ECOG-ACRIN E3805 Investigators, Sweeney CJ. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate. 2022 09; 82(12):1176-1185. PMID: 35538398; PMCID: PMC9839346.
      Citations: 2     Fields:    Translation:Humans
    4. Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559. PMID: 35110415; PMCID: PMC9012680.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    5. Autio KA, Antonarakis ES, Mayer TM, Shevrin DH, Stein MN, Vaishampayan UN, Morris MJ, Slovin SF, Heath EI, Tagawa ST, Rathkopf DE, Milowsky MI, Harrison MR, Beer TM, Balar AV, Armstrong AJ, George DJ, Paller CJ, Apollo A, Danila DC, Graff JN, Nordquist L, Dayan Cohn ES, Tse K, Schreiber NA, Heller G, Scher HI. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol Open Sci. 2021 Dec; 34:70-78. PMID: 34934969; PMCID: PMC8655386.
      Citations: 1     
    6. Morris MJ, Sweeney CJ, Ryan CJ, Shevrin DH, Antonarakis ES, Pandit-Taskar N, Jacene HA, Vesselle H, Petrenciuc O, Lu C, Carrasquillo JA, Higano CS, Loriot Y, Fizazi K, Deandreis D. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116. PMID: 31082669; PMCID: PMC7474951.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    7. Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536. PMID: 29417827; PMCID: PMC5941708.
      Citations:    Fields:    Translation:HumansPHPublic Health
    8. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087. PMID: 29384722; PMCID: PMC5891129.
      Citations: 328     Fields:    Translation:HumansCTClinical Trials
    9. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999. PMID: 29261439; PMCID: PMC6075827.
      Citations: 97     Fields:    Translation:HumansCellsCTClinical Trials
    10. Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ, ECOG-ACRIN 3805 Investigators. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382. PMID: 29261442; PMCID: PMC5805480.
      Citations: 35     Fields:    Translation:Humans
    11. Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747. PMID: 27989354; PMCID: PMC5535082.
      Citations: 133     Fields:    Translation:Humans
    12. Penson DF, Lin DW, Karsh L, Quinn DI, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. PMID: 27528114; PMCID: PMC5116579.
      Citations: 1     Fields:    Translation:Humans
    13. Shevrin DH. Genomic predictors for treatment of late stage prostate cancer. Asian J Androl. 2016 Jul-Aug; 18(4):586-91. PMID: 27030083; PMCID: PMC4955183.
      Citations: 6     Fields:    Translation:Humans
    14. Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, Li J, Dickow B, Heath E, Smith D, Fontana J. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology. 2015 Dec; 86(6):1206-11. PMID: 26375845; PMCID: PMC6902637.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    15. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46. PMID: 26244877; PMCID: PMC4562797.
      Citations: 918     Fields:    Translation:Humans
    16. Xu W, Neill T, Yang Y, Hu Z, Cleveland E, Wu Y, Hutten R, Xiao X, Stock SR, Shevrin D, Kaul K, Brendler C, Iozzo RV, Seth P. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015 Mar; 22(3):247-56. PMID: 25503693; PMCID: PMC4361227.
      Citations: 52     Fields:    Translation:HumansAnimalsCells
    17. Pascal LE, Masoodi KZ, O'Malley KJ, Shevrin D, Gingrich JR, Parikh RA, Wang Z. 5a-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol. 2015 Apr; 193(4):1388-93. PMID: 25444984; PMCID: PMC4404193.
      Citations: 4     Fields:    Translation:Animals
    18. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    19. Masoodi KZ, Ramos Garcia R, Pascal LE, Wang Y, Ma HM, O'Malley K, Eisermann K, Shevrin DH, Nguyen HM, Vessella RL, Nelson JB, Parikh RA, Wang Z. 5a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013 Jul; 154(7):2296-307. PMID: 23671262; PMCID: PMC3689274.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    20. Victorson DE, Brucker PS, Bode RK, Eton DT, Talcott JA, Clark JA, Knight SJ, Litwin MS, Moinpour CM, Reeve BB, Aaronson NK, Bennett CL, Herr HW, McGuire M, Shevrin D, McVary K, Cella D. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31. PMID: 23522840.
      Citations: 1     Fields:    Translation:Humans
    21. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92. PMID: 22006050; PMCID: PMC4312616.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    22. Gupta S, Wang Y, Ramos-Garcia R, Shevrin D, Nelson JB, Wang Z. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85. PMID: 20564326; PMCID: PMC3076187.
      Citations: 7     Fields:    Translation:HumansAnimals
    23. Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology. 2011 Sep; 20(9):977-83. PMID: 20661866.
      Citations: 12     Fields:    Translation:Humans
    24. Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23. PMID: 20230544.
      Citations: 17     Fields:    Translation:Humans
    25. Wang Y, Gupta S, Hua V, Ramos-Garcia R, Shevrin D, Jovanovic BD, Nelson JB, Wang Z. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate. 2010 Feb 01; 70(2):147-54. PMID: 19739129; PMCID: PMC2805824.
      Citations: 9     Fields:    Translation:AnimalsCells
    26. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43. PMID: 18413835; PMCID: PMC5648051.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    27. Butt Z, Wagner LI, Beaumont JL, Paice JA, Peterman AH, Shevrin D, Von Roenn JH, Carro G, Straus JL, Muir JC, Cella D. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage. 2008 Jan; 35(1):20-30. PMID: 17959345.
      Citations: 63     Fields:    Translation:Humans
    28. Butt Z, Wagner LI, Beaumont JL, Paice JA, Straus JL, Peterman AH, Carro G, Von Roenn JH, Shevrin D, Cella D. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer. 2008 Feb; 16(2):151-9. PMID: 17609992.
      Citations: 9     Fields:    Translation:Humans
    29. Lai JS, Cella D, Dineen K, Bode R, Von Roenn J, Gershon RC, Shevrin D. An item bank was created to improve the measurement of cancer-related fatigue. J Clin Epidemiol. 2005 Feb; 58(2):190-7. PMID: 15680754.
      Citations: 33     Fields:    Translation:Humans
    30. Yount S, Cella D, Banik D, Ashraf T, Shevrin D. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes. 2003 Nov 21; 1:69. PMID: 14633279; PMCID: PMC305353.
      Citations: 10     Fields:    Translation:Humans
    31. Masters GA, Hahn EA, Shevrin DH, Kies MS. Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):221-6. PMID: 12581577.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    32. Lind SE, Caprini JA, Goldshteyn S, Dohnal JC, Vesely SK, Shevrin DH. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost. 2003 Jan; 89(1):185-9. PMID: 12540969.
      Citations: 1     Fields:    Translation:Humans
    33. Kucuk O, Shevrin DH, Pandya KJ, Bonomi PD. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5. PMID: 10955866.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    34. Lind SE, Goldshteyn S, Barry CP, Lindquist JR, Piergies AA, Rosen T, Schneider JR, Shevrin DH, Caprini JA. Assessment of coagulation system activation using spot urine measurements. Blood Coagul Fibrinolysis. 1999 Jul; 10(5):285-9. PMID: 10456620.
      Citations: 1     Fields:    Translation:Humans
    35. Shevrin DH, Lad TE, Guinan P, Kilton LJ, Greenburg A, Johnson P, Blough RR, Hoyer H. Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs. 1994; 12(1):65-6. PMID: 7960609.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    36. Shevrin DH, Kilton LJ, Lad TE, Mullane M, Esparaz B, Knop R, Egner J, Johnson P, Blough R, French S, et al. Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study. Invest New Drugs. 1994; 12(4):345-6. PMID: 7775139.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    37. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vogelzang NJ, Blough R, Benson AB. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993 Sep 15; 72(6):1965-8. PMID: 8364875.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    38. Lee C, Shevrin DH, Kozlowski JM. In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Metastasis Rev. 1993 Mar; 12(1):21-8. PMID: 8448823.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    39. Bressler LR, Murphy CM, Shevrin DH, Warren RF. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993 Feb; 27(2):182-5. PMID: 8439695.
      Citations: 1     Fields:    Translation:Humans
    40. Shevrin DH, Gorny KI, Rosol TJ, Kukreja SC. Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate. 1991; 19(2):149-54. PMID: 1923962.
      Citations: 6     Fields:    Translation:AnimalsCells
    41. Kukreja SC, Rosol TJ, Wimbiscus SA, Shevrin DH, Grill V, Barengolts EI, Martin TJ. Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. Endocrinology. 1990 Jul; 127(1):305-10. PMID: 2361475.
      Citations: 7     Fields:    Translation:AnimalsCells
    42. Barengolts E, Buschmann R, Shevrin DH, Abramson EC, Kukreja SC. Effects of hypercalcemia-producing tumor extract and parathyroid hormone on osteoclast ultrastructure. Acta Anat (Basel). 1990; 137(2):160-4. PMID: 2316331.
      Citations: 1     Fields:    Translation:HumansCells
    43. Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Blough RR, Weidner LL, Vogelzang NJ. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3. PMID: 2477345.
      Citations: 3     Fields:    Translation:Humans
    44. Kukreja SC, York PA, Nalbantian-Brandt C, Shevrin DH, Favus MJ. Effect of hypercalcemia-producing tumor on 1,25(OH)2D3 biosynthesis in athymic mice. Am J Physiol. 1989 Feb; 256(2 Pt 1):E309-14. PMID: 2919669.
      Citations:    Fields:    Translation:HumansAnimals
    45. Shevrin DH, Gorny KI, Kukreja SC. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate. 1989; 15(2):187-94. PMID: 2529482.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    46. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI, Martin TJ. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest. 1988 Nov; 82(5):1798-802. PMID: 2846659; PMCID: PMC442751.
      Citations: 17     Fields:    Translation:HumansAnimals
    47. Abramson EC, Chang J, Mayer M, Kukla LJ, Shevrin DH, Lad TE, Buschman R, Kukreja SC. Effects of cisplatin on parathyroid hormone- and human lung tumor-induced bone resorption. J Bone Miner Res. 1988 Oct; 3(5):541-6. PMID: 3195366.
      Citations: 1     Fields:    Translation:HumansAnimals
    48. Shipley PJ, Shevrin DH, Kukreja SC. Increased renal calcium reabsorption in an animal model of hypercalcemia of human malignancy. J Bone Miner Res. 1988 Oct; 3(5):555-60. PMID: 3195367.
      Citations: 1     Fields:    Translation:HumansAnimals
    49. Fukumoto M, Shevrin DH, Roninson IB. Analysis of gene amplification in human tumor cell lines. Proc Natl Acad Sci U S A. 1988 Sep; 85(18):6846-50. PMID: 3413126; PMCID: PMC282075.
      Citations: 4     Fields:    Translation:HumansCells
    50. Shevrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis. 1988 Sep-Oct; 6(5):401-9. PMID: 3378377.
      Citations: 15     Fields:    Translation:AnimalsCells
    51. Kukreja SC, Rosol TJ, Shevrin DH, York PA. Quantitative bone histomorphometry in nude mice bearing a human squamous cell lung cancer. J Bone Miner Res. 1988 Jun; 3(3):341-6. PMID: 3213626.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    52. Shevrin DH, Lad TE, Kukreja SC. Effect of epidermal growth factor infusion on serum and urine calcium in mice. J Bone Miner Res. 1987 Aug; 2(4):297-301. PMID: 3502678.
      Citations: 3     Fields:    Translation:Animals
    53. Lad TE, Mishoulam HM, Shevrin DH, Kukla LJ, Abramson EC, Kukreja SC. Treatment of cancer-associated hypercalcemia with cisplatin. Arch Intern Med. 1987 Feb; 147(2):329-32. PMID: 3813752.
      Citations: 3     Fields:    Translation:Humans
    54. Shevrin DH, McGuire WP, Lanzotti V, Krauss S, Blough R, Cobleigh M, Johnson C, Lad T, Kukla L. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8. PMID: 3955556.
      Citations: 1     Fields:    Translation:Humans
    55. Cobleigh MA, Hill JH, Gallagher PA, Kukla LJ, Lad TE, Shevrin DH, Applebaum EL, McGuire WP. A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck. Cancer. 1985 Dec 01; 56(11):2573-5. PMID: 4052934.
      Citations: 3     Fields:    Translation:Humans
    56. Shevrin DH, Bressler LR, McGuire WP, Kukreja SC, Kukla LJ, Lad TE. Treatment of cancer-associated hypercalcemia with mithramycin and oral etidronate disodium. Clin Pharm. 1985 Mar-Apr; 4(2):204-5. PMID: 2985326.
      Citations:    Fields:    Translation:Humans
    57. Kukla LJ, Abramson EC, McGuire WP, Shevrin DH, Lad T, Kukreja SC. Cis-platinum treatment for malignancy-associated humoral hypercalcemia in an athymic mouse model. Calcif Tissue Int. 1984 Sep; 36(5):559-62. PMID: 6441629.
      Citations: 1     Fields:    Translation:HumansAnimals
    58. Abramson EC, Kukla LJ, Shevrin DH, Lad TE, McGuire WP, Kukreja SC. A model for malignancy-associated humoral hypercalcemia. Calcif Tissue Int. 1984 Sep; 36(5):563-7. PMID: 6441630.
      Citations: 3     Fields:    Translation:HumansAnimals
    Shevrin's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (265)
    Co-Authors (12)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors